Calcitonin gene-related peptide (CGRP) plays a pivotal role in the pathophysiology of migraine and is an important therapeutic target. Monoclonal antibodies that inhibit CGRP binding to its receptor ...

BARCELONA — Patients with migraine are less likely to respond to CGRP monoclonal antibody (mAb) preventive treatments if they have certain psychiatric disorders, a new study shows. Italian researchers ...

For Cherise Irons, chocolate, red wine, and aged cheeses are dangerous. So are certain sounds, perfumes and other strong scents, cold weather, and thunderstorms. Stress and lack of sleep, too. She ...

Advancements in migraine research over the past few decades have led researchers to identify the possible role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. CGRP is a ...

The approval of medicines called “CGRP antagonists” has led to big changes in how migraines are managed. These medicines work in a different way than older medicines to treat or prevent migraine. The ...

The US Food and Drug Administration (FDA) has recently approved Zavegepant, a new migraine treatment from Pfizer that will be available in July, Time reports. This nasal spray is the first of its kind ...

SAN DIEGO — Migraine is the third most common neurological disorder worldwide, and yet reliable treatments remain elusive. Research hinting at new avenues for treatments will be presented at ...

When women suffer migraine attacks, it is often just before or during their monthly period. A team of researchers from Charité – Universitätsmedizin Berlin has now identified a possible explanation.

Migraines are far more than just bad headaches. They are a complex, chronic neurological condition that affects more than a billion people worldwide and ranks among the top causes of disability across ...

On Mar. 10, the U.S. Food and Drug Administration (FDA) approved a new treatment for migraines given as a nasal spray, according to the drug’s maker, Pfizer. Zavegepant (brand name: Zavzpret), is the ...

One class of drugs has already found success in treating the painful, disorienting and common attacks. Excitement is building about a slew of additional drug targets. By Amber Dance/Knowable Magazine ...